Novo Nordisk Grabs Shark Antibody-Based CNS Delivery Technology From Ossianix
Executive Summary
Being able to move therapeutic molecules for diabetes and other metabolic diseases into the CNS is the aim of a research collaboration and option agreement between Novo Nordisk and the six-year-old US biotech, Ossianix.
You may also be interested in...
Novo Nordisk Cuts 400 Jobs In R&D Reshuffle As It Broadens Its Horizons
Novo, which is under pressure to diversify and signaled plans to cut jobs back in August, will lay off 400 people as it reallocates resources to more efficiently bring in novel products through both R&D and business development, continuing a deal-making spree that's already under way.
Evotec's CEO Explains Logic Behind Drug Discovery Pact With Novo Nordisk
Novo Nordisk's R&D pact with Evotec will open therapeutic possibilities for the Danish group in diabetes and obesity using small molecules, says Evotec's CEO.
Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina
Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration.
Need a specific report? 1000+ reports available
Buy Reports